CN113150112B - 抗人乳头瘤病毒16 e7的t细胞受体 - Google Patents

抗人乳头瘤病毒16 e7的t细胞受体 Download PDF

Info

Publication number
CN113150112B
CN113150112B CN202110399056.9A CN202110399056A CN113150112B CN 113150112 B CN113150112 B CN 113150112B CN 202110399056 A CN202110399056 A CN 202110399056A CN 113150112 B CN113150112 B CN 113150112B
Authority
CN
China
Prior art keywords
seq
leu
amino acid
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110399056.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113150112A (zh
Inventor
克里斯蒂安·S·欣里西斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CN202110399056.9A priority Critical patent/CN113150112B/zh
Publication of CN113150112A publication Critical patent/CN113150112A/zh
Application granted granted Critical
Publication of CN113150112B publication Critical patent/CN113150112B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
CN202110399056.9A 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体 Active CN113150112B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110399056.9A CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462004335P 2014-05-29 2014-05-29
US62/004,335 2014-05-29
CN201580031789.XA CN106661098B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体
PCT/US2015/033129 WO2015184228A1 (en) 2014-05-29 2015-05-29 Anti-human papillomavirus 16 e7 t cell receptors
CN202110399056.9A CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580031789.XA Division CN106661098B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Publications (2)

Publication Number Publication Date
CN113150112A CN113150112A (zh) 2021-07-23
CN113150112B true CN113150112B (zh) 2024-02-06

Family

ID=53396593

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110399056.9A Active CN113150112B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体
CN201580031789.XA Active CN106661098B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580031789.XA Active CN106661098B (zh) 2014-05-29 2015-05-29 抗人乳头瘤病毒16 e7的t细胞受体

Country Status (21)

Country Link
US (4) US10174098B2 (cg-RX-API-DMAC7.html)
EP (3) EP3689900B1 (cg-RX-API-DMAC7.html)
JP (5) JP6742991B2 (cg-RX-API-DMAC7.html)
KR (2) KR102618267B1 (cg-RX-API-DMAC7.html)
CN (2) CN113150112B (cg-RX-API-DMAC7.html)
AU (5) AU2015266818B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027805A2 (cg-RX-API-DMAC7.html)
CA (1) CA2950192A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122790T1 (cg-RX-API-DMAC7.html)
DK (1) DK3149031T3 (cg-RX-API-DMAC7.html)
ES (1) ES2784237T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200376T1 (cg-RX-API-DMAC7.html)
IL (3) IL290655B2 (cg-RX-API-DMAC7.html)
LT (1) LT3149031T (cg-RX-API-DMAC7.html)
MX (2) MX375379B (cg-RX-API-DMAC7.html)
PL (1) PL3149031T3 (cg-RX-API-DMAC7.html)
PT (1) PT3149031T (cg-RX-API-DMAC7.html)
SA (1) SA516380394B1 (cg-RX-API-DMAC7.html)
SI (1) SI3149031T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000143T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015184228A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10174098B2 (en) * 2014-05-29 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E7 T cell receptors
AU2016258845B2 (en) * 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CA3007262A1 (en) 2015-12-03 2017-06-08 Lucas James Thompson Modified chimeric receptors and related compositions and methods
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
ES2912269T3 (es) 2016-09-27 2022-05-25 Cero Therapeutics Inc Moléculas de receptor de engullimiento quimérico
MA46354A (fr) 2016-10-03 2019-08-07 Juno Therapeutics Inc Molécules se liant spécifiquement au vph
MX2019006374A (es) * 2016-12-02 2019-09-11 Univ Southern California Receptores inmunes sinteticos y metodos de usos de ellos.
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
KR20200005655A (ko) * 2017-05-15 2020-01-15 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 비시스트론성 키메라성 항원 수용체 및 이의 용도
WO2019005897A1 (en) * 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
MX2020007266A (es) 2017-09-26 2020-09-07 Cero Therapeutics Inc Moleculas del receptor quimerico de engullido y metodos de uso.
KR20250024096A (ko) 2017-09-29 2025-02-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 p53을 인식하는 t 세포 수용체
CN111954679A (zh) 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
CA3077595A1 (en) 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
CN111556893A (zh) 2017-11-06 2020-08-18 爱迪塔斯医药股份有限公司 免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US20210052647A1 (en) 2018-02-09 2021-02-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
AU2019243153A1 (en) * 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
US12291557B2 (en) 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof
US12303551B2 (en) 2018-03-28 2025-05-20 Cero Therapeutics Holdings, Inc. Cellular immunotherapy compositions and uses thereof
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
CA3095084A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
MX2020010459A (es) 2018-04-05 2021-01-20 Juno Therapeutics Inc Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
US12415845B2 (en) 2018-04-24 2025-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
US20210155941A1 (en) * 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
US20220372106A1 (en) 2018-11-30 2022-11-24 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CA3144054A1 (en) * 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CA3144070A1 (en) 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN110357952B (zh) * 2019-07-17 2022-03-22 深圳市因诺转化医学研究院 识别人乳头瘤病毒hpv16-e7抗原的tcr
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
WO2021135178A1 (zh) * 2019-12-30 2021-07-08 华夏英泰（北京）生物技术有限公司 一种增强型t细胞受体star及其应用
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
US20240148869A1 (en) * 2020-05-07 2024-05-09 China Immunotech (Beijing) Biotechnology Co., Ltd Improved T cell receptor-costimulatory molecule chimera
EP4159768A4 (en) * 2020-05-25 2024-11-20 Bristar Immunotech Limited Enhanced synthetic t-cell receptor and antigen receptor
WO2021252517A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
CA3191186A1 (en) 2020-09-04 2022-03-10 Sanghyun Kim T cell receptors recognizing r273c or y220c mutations in p53
WO2022060904A1 (en) * 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
US20220372165A1 (en) 2021-05-05 2022-11-24 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2022236050A1 (en) 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023274382A1 (zh) * 2021-06-30 2023-01-05 华夏英泰（北京）生物技术有限公司 一种多靶点合成t细胞受体抗原/抗体受体及其应用
WO2023036169A1 (en) * 2021-09-07 2023-03-16 Corregene Biotechnology Co., Ltd. Antigen binding proteins and uses thereof
US20250289866A1 (en) * 2021-10-18 2025-09-18 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
KR20240112996A (ko) * 2021-11-10 2024-07-19 티스캔 테라퓨틱스, 인크. Hpv16 e7 항원을 인식하는 결합 단백질 및 이의 용도
CA3247928A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
CN117402232A (zh) * 2022-05-10 2024-01-16 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
JP2025531268A (ja) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Ｔ細胞機能を調節するための組成物、システム、および方法
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途
KR20250174626A (ko) 2023-03-27 2025-12-12 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 P53의 y220c 또는 r175h 돌연변이를 표적화하는 t 세포 수용체
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025096419A1 (en) * 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025193926A1 (en) 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting e545k or n345k mutation in pik3ca
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
CN102695717A (zh) * 2009-09-29 2012-09-26 Ucl商务股份有限公司 T细胞受体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (cg-RX-API-DMAC7.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
EP2985291B1 (en) * 2005-04-01 2018-09-19 Immunocore Limited High affinity hiv t cell receptors
EP3584251A3 (en) 2007-05-31 2020-01-29 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
US10174098B2 (en) * 2014-05-29 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E7 T cell receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
CN102695717A (zh) * 2009-09-29 2012-09-26 Ucl商务股份有限公司 T细胞受体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers;Angelika B Riemer等;J Biol Chem;第285卷(第38期);29608-29622 *
Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line;Sarah J Youde等;Int J Cancer;第114卷(第4期);606-612 *
Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens;Derin B Keskin等;Front Immunol;第2卷;1-26 *
Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer;Kirsten B J Scholten等;Clin Immunol;第114卷(第2期);119-129 *
Promiscuous behavior of HPV16E6 specific T cell receptor beta chains hampers functional expression in TCR transgenic T cells, which can be restored in part by genetic modification;Kirsten B J Scholten等;Cell Oncol;第32卷(第1-2期);43-56 *

Also Published As

Publication number Publication date
JP6997267B2 (ja) 2022-02-04
EP3689900A1 (en) 2020-08-05
CA2950192A1 (en) 2015-12-03
AU2019283892B2 (en) 2021-01-28
EP3149031A1 (en) 2017-04-05
JP2022058360A (ja) 2022-04-12
AU2015266818A1 (en) 2016-11-24
AU2019283892A1 (en) 2020-01-23
JP2017524372A (ja) 2017-08-31
SI3149031T1 (sl) 2020-07-31
MX2020010035A (es) 2020-10-14
MX375379B (es) 2025-03-06
PT3149031T (pt) 2020-03-25
AU2023200608B2 (en) 2024-08-22
EP3689900B1 (en) 2025-07-23
IL248797B (en) 2021-05-31
JP6742991B2 (ja) 2020-08-19
CN106661098A (zh) 2017-05-10
SMT202000143T1 (it) 2020-05-08
US10174098B2 (en) 2019-01-08
IL248797A0 (en) 2017-01-31
EP3149031B1 (en) 2019-12-18
BR112016027805A2 (pt) 2017-10-24
PL3149031T3 (pl) 2020-08-24
CY1122790T1 (el) 2021-05-05
WO2015184228A1 (en) 2015-12-03
KR102445667B1 (ko) 2022-09-21
ES2784237T3 (es) 2020-09-23
AU2021202227B2 (en) 2022-11-10
MX2016015383A (es) 2017-02-28
US20220372103A1 (en) 2022-11-24
KR20170003939A (ko) 2017-01-10
IL282518A (en) 2021-06-30
US20210130432A1 (en) 2021-05-06
EP4609876A2 (en) 2025-09-03
IL290655B1 (en) 2024-01-01
IL290655B2 (en) 2024-05-01
US20190085047A1 (en) 2019-03-21
AU2024266702A1 (en) 2024-12-12
US20170145070A1 (en) 2017-05-25
KR20220130267A (ko) 2022-09-26
US11434272B2 (en) 2022-09-06
LT3149031T (lt) 2020-05-25
JP2023110036A (ja) 2023-08-08
IL290655A (en) 2022-04-01
JP7291196B2 (ja) 2023-06-14
CN106661098B (zh) 2021-05-04
AU2021202227A1 (en) 2021-05-06
HRP20200376T1 (hr) 2020-08-07
DK3149031T3 (da) 2020-03-16
US10870687B2 (en) 2020-12-22
AU2015266818B2 (en) 2019-10-03
CN113150112A (zh) 2021-07-23
IL282518B (en) 2022-04-01
JP2024156861A (ja) 2024-11-06
JP2021000089A (ja) 2021-01-07
JP7744479B2 (ja) 2025-09-25
KR102618267B1 (ko) 2023-12-27
SA516380394B1 (ar) 2021-01-05
JP7535158B2 (ja) 2024-08-15
AU2023200608A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
AU2021202227B2 (en) Anti-human papillomavirus 16 E7 T cell receptors
KR102520488B1 (ko) 키메라 항원 수용체-변형된 nk-92 세포(chimeric antigen receptor-modified nk-92 cells)
AU2014211454B2 (en) High avidity binding molecules recognizing MAGE-A1
JP6133209B2 (ja) 抗ｓｓｘ−２ｔ細胞受容体及び関連材料並びに使用方法
CN108350462B (zh) 嵌合抗原受体及其用途
US6573058B1 (en) Antibody to herpes virus entry receptor protein
US20040208850A1 (en) Modified vaccinia ankara expressing p53 in cancer immunotherapy
TW202332690A (zh) 用於使用融合蛋白之ｔｃｒ重編程的組合物及方法
JP2018531014A6 (ja) 抗ｃｄ３０キメラ抗原受容体
JP2018531014A (ja) 抗ｃｄ３０キメラ抗原受容体
CN112979807B (zh) Bcma结合抗体及其用途
CN106591371A (zh) Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
AU2023202642A1 (en) IL-2 Dependent NK-92 cells with stable Fc receptor expression
CN108913718A (zh) 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
CN108103088B (zh) 重组GLP-1类似物Fc融合蛋白的优化基因及其应用
KR20210137427A (ko) Car t 세포 방법 및 작제물
HK40056926A (en) Anti-human papillomavirus 16 e7 t cell receptors
HK40056926B (zh) 抗人乳头瘤病毒16e7 的t细胞受体
CN114891115B (zh) 一种car细胞疗法用核酸构建体及其慢病毒载体、细胞制剂和应用
CN109022363A (zh) 一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
CN111961651B (zh) 基因重组PD-1抗体自分泌型人γδT细胞及其构建方法和应用
CN117377683A (zh) 新抗原肽及其在治疗braf基因突变相关疾病中的用途
RU2726541C1 (ru) Рекомбинантная клеточная линия рака молочной железы человека BrCCh4e-134, экспрессирующая простат-специфический мембранный антиген человека
CN110819589A (zh) 一种增强免疫效应细胞功能的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056926

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant